---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-095155"
form_type: "8-K"
ticker: "ADTX"
cik: "0001726711"
company_name: "Aditxt, Inc."
filed_at: "2023-12-12T23:59:59+00:00"
generated_at: "2026-06-07T14:18:08.811048+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aditxt to acquire Evofem in stock merger; assumes ~$100M debt, targets women's health market

## Summary
- Evofem shareholders to receive 610K shares of Aditxt common and 2,327 shares of Series A-1 preferred.
- Aditxt assumes ~$100M senior indebtedness; issues $5M Jan 2024 secured notes, $8M Sep 2024 secured notes, $5M unsecured notes.
- Evofem's Phexxi net sales $13.4M for first 9 months 2023; non-hormonal contraceptive market projected $27.7B to $52.2B by 2031.
- Closing requires shareholder approvals, SEC S-4 effectiveness, Nasdaq compliance, and warrant/note holder agreements.
- Aditxt must provide $3M loan to Evofem by Jan 31, 2024; deal may be terminated if not closed by May 8, 2024.

## SEC filing metadata
- accession: 0001213900-23-095155
- form_type: 8-K
- ticker: ADTX
- cik: 0001726711
- company_name: Aditxt, Inc.
- filed_at: 2023-12-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726711/000121390023095155/0001213900-23-095155-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726711/000121390023095155/ea189850-8k425_aditxtinc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-095155
- JSON: https://secwatch.observer/filing/0001213900-23-095155.json
- Plain text: https://secwatch.observer/filing/0001213900-23-095155.txt

## Key facts
- Debt Financings
  Aditxt, Inc. incurred senior notes.
  - Instrument: senior notes
  - Event: incurrence
  source text: Reference is made to the disclosure under Item 1.01 above with respect to the December 2023 Secured Notes, September 2024 Secured Notes and the Royalty Note
  evidence_url: https://www.sec.gov/Archives/edgar/data/1726711/000121390023095155/0001213900-23-095155-index.htm
- Material Agreements
  Aditxt, Inc. entered into Agreement and Plan of Merger with Evofem Biosciences, Inc. valued at Merger Sub will be merged into and with Evofem, with Evofem surviving as a wholly owned subsidiary o (effective 2023-12-11).
  - Action: entry
  - Agreement: merger
  - Counterparty: Evofem Biosciences, Inc.
  - Value: Merger Sub will be merged into and with Evofem, with Evofem surviving as a wholly owned subsidiary o
  - Effective: 2023-12-11
  source text: On December 11, 2023 (the " Execution Date "), Aditxt, Inc., a Delaware corporation (the " Company ") entered into an Agreement and Plan of Merger (the " Merger Agreement ") with Adicure, Inc., a Delaware corporation and wholly owned subsidiary of the Company (" Merger Sub ") and Evofem Biosciences, Inc., a Delaware corporation (" Evofem "), pursuant to which, Merger Sub will be merged into and with Evofem (the " Merger "), with Evofem surviving the Merger as a wholly owned subsidiary of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1726711/000121390023095155/0001213900-23-095155-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.